drugset / Trial / NCT01267994
A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease
Phase 1/2
Completed
13 enrolled
Andrea Vambutas
National Institute on Deafness and Other Communication Disorders (NIDCD) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if Anakinra (an interleukin-1 receptor antagonist) can improve hearing thresholds in those patients with Autoimmune Inner Ear Disease (AIED) that did not respond to oral steroid therapy for a sudden decline in hearing. The patients to be enrolled will have recently completed a course of oral steroids and demonstrated no change in their audiometric thresholds following corticosteroid therapy.
Timeline
- Start
- 2011-06
- Primary completion
- 2014-09
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anakinra | Protein / enzyme biologic | 100 mg | Subcutaneous |